{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:17Z","timestamp":1793316257716,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12223-w","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:50:10Z","timestamp":1783014610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Decoding PARP roles in breast cancer therapy resistance"],"prefix":"10.1007","volume":"53","author":[{"given":"Mohammad","family":"Abohassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4406-5265","authenticated-orcid":false,"given":"Farag M.","family":"Altalbawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid S.","family":"Jabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thikra F.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashishkumar","family":"Kyada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Nathiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parjinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munthar Kadhim","family":"Abosaoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"6","key":"12223_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A et al (2019) Breast cancer statistics, 2019. CA: A Cancer. J Clin 69(6):438\u2013451. https:\/\/doi.org\/10.3322\/caac.21583","journal-title":"J Clin"},{"key":"12223_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.breast.2020.09.006","volume":"54","author":"Y Han","year":"2020","unstructured":"Han Y, Wang J, Xu B (2020) Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. Breast 54:114\u2013120. https:\/\/doi.org\/10.1016\/j.breast.2020.09.006","journal-title":"Breast"},{"key":"12223_CR3","doi-asserted-by":"publisher","unstructured":"Haque MM, Desai KV (2019) Pathways to Endocrine Therapy Resistance in Breast Cancer. Front Endocrinol (Lausanne) 10:573. PMID: 31496995; PMCID: PMC6712962 https:\/\/doi.org\/10.3389\/fendo.2019.00573","DOI":"10.3389\/fendo.2019.00573"},{"issue":"5","key":"12223_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2174\/156800910791517226","volume":"10","author":"RA Madaio","year":"2010","unstructured":"Madaio RA, Spalletta G, Cravello L, Ceci M, Repetto L, Naso G (2010) Overcoming endocrine resistance in breast cancer. Curr Cancer Drug Targets 10(5):519\u2013528. https:\/\/doi.org\/10.2174\/156800910791517226","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"12223_CR5","doi-asserted-by":"publisher","first-page":"1715766","DOI":"10.1080\/23723556.2020.1715766","volume":"7","author":"WW Feng","year":"2020","unstructured":"Feng WW, Bang S, Kurokawa M (2020) CD36: a key mediator of resistance to HER2 inhibitors in breast cancer. Mol Cell Oncol 7(2):1715766. https:\/\/doi.org\/10.1080\/23723556.2020.1715766","journal-title":"Mol Cell Oncol"},{"issue":"8","key":"12223_CR6","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/0008-5472.Can-16-2976","volume":"77","author":"B Ruprecht","year":"2017","unstructured":"Ruprecht B, Zaal EA, Zecha J, Wu W, Berkers CR, Kuster B et al (2017) Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis. Cancer Res 77(8):1842\u20131853. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-2976","journal-title":"Cancer Res"},{"key":"12223_CR7","doi-asserted-by":"publisher","first-page":"12156","DOI":"10.1038\/ncomms12156","volume":"7","author":"G Deblois","year":"2016","unstructured":"Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P et al (2016) ERR\u03b1 mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun 7:12156. https:\/\/doi.org\/10.1038\/ncomms12156","journal-title":"Nat Commun"},{"issue":"11","key":"12223_CR8","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/1541-7786.Mcr-19-0756","volume":"17","author":"V Sethunath","year":"2019","unstructured":"Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N et al (2019) Targeting the mevalonate pathway to overcome acquired anti-her2 treatment resistance in breast cancer. Mol Cancer Res 17(11):2318\u20132330. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-19-0756","journal-title":"Mol Cancer Res"},{"key":"12223_CR9","doi-asserted-by":"publisher","first-page":"790967","DOI":"10.3389\/fonc.2021.790967","volume":"11","author":"H Sha","year":"2021","unstructured":"Sha H, Gan Y, Zou R, Wu J, Feng J. Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer. Front Oncol. 2021 Dec 16;11:790967. PMID: 34976832; PMCID: PMC8716401. https:\/\/doi.org\/10.3389\/fonc.2021.790967","journal-title":"Front Oncol"},{"issue":"19","key":"12223_CR10","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1093\/nar\/gkw675","volume":"44","author":"I Talhaoui","year":"2016","unstructured":"Talhaoui I, Lebedeva NA, Zarkovic G, Saint-Pierre C, Kutuzov MM, Sukhanova MV et al (2016) Poly(ADP-ribose) polymerases covalently modify strand break termini in DNA fragments in vitro. Nucleic Acids Res 44(19):9279\u20139295. https:\/\/doi.org\/10.1093\/nar\/gkw675","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"12223_CR11","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1128\/MCB.23.16.5919-5927.2003","volume":"23","author":"JB Leppard","year":"2003","unstructured":"Leppard JB, Dong Z, Mackey ZB, Tomkinson AE (2003) Physical and Functional Interaction between DNA Ligase III\u03b1 and Poly(ADP-Ribose) Polymerase 1 in DNA Single-Strand Break Repair. Mol Cell Biol 23(16):5919\u20135927. https:\/\/doi.org\/10.1128\/MCB.23.16.5919-5927.2003","journal-title":"Mol Cell Biol"},{"key":"12223_CR12","doi-asserted-by":"publisher","first-page":"119556","DOI":"10.1016\/j.lfs.2021.119556","volume":"277","author":"R Sadhukhan","year":"2021","unstructured":"Sadhukhan R, Ghosh U (2021) PARP1 modulates telomere sister chromatid exchange and telomere length homeostasis by regulating telomere localization of SLX4 in U2OS cells. Life Sci 277:119556. https:\/\/doi.org\/10.1016\/j.lfs.2021.119556","journal-title":"Life Sci"},{"issue":"11","key":"12223_CR13","first-page":"1033","volume":"25","author":"RP Roop","year":"2011","unstructured":"Roop RP, Ma CX, Ellis MJ (2011) PARP inhibitors and their evolving role in breast cancer. Oncol (Williston Park) 25(11):1033\u20131034","journal-title":"Oncol (Williston Park)"},{"issue":"1","key":"12223_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C et al (2025) Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer 24(1):156. https:\/\/doi.org\/10.1186\/s12943-025-02355-1","journal-title":"Mol Cancer"},{"issue":"23","key":"12223_CR15","doi-asserted-by":"publisher","first-page":"R1256","DOI":"10.1016\/j.cub.2017.09.054","volume":"27","author":"AK Leung","year":"2017","unstructured":"Leung AK, PARPs (2017) Curr Biol 27(23):R1256\u2013R8","journal-title":"Curr Biol"},{"issue":"8","key":"12223_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/carcin\/bgs132","volume":"33","author":"FG Sousa","year":"2012","unstructured":"Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JAP, Larsen AK et al (2012) PARPs and the DNA damage response. Carcinogenesis 33(8):1433\u20131440. https:\/\/doi.org\/10.1093\/carcin\/bgs132","journal-title":"Carcinogenesis"},{"issue":"10","key":"12223_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer SM, van Attikum HPARP, Inhibitor Resistance (2019) A Tug-of-War in BRCA-Mutated Cells. Trends Cell Biol 29(10):820\u2013834. https:\/\/doi.org\/10.1016\/j.tcb.2019.07.008","journal-title":"Trends Cell Biol"},{"issue":"5","key":"12223_CR18","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/nar\/gkw1246","volume":"45","author":"H Hanzlikova","year":"2017","unstructured":"Hanzlikova H, Gittens W, Krejcikova K, Zeng Z, Caldecott KW (2017) Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res 45(5):2546\u20132557. https:\/\/doi.org\/10.1093\/nar\/gkw1246","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"12223_CR19","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1093\/nar\/gkl840","volume":"34","author":"M Wang","year":"2006","unstructured":"Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H et al (2006) PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 34(21):6170\u20136182. https:\/\/doi.org\/10.1093\/nar\/gkl840","journal-title":"Nucleic Acids Res"},{"key":"12223_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fmolb.2020.00191","volume":"7","author":"D Harrision","year":"2020","unstructured":"Harrision D, Gravells P, Thompson R, Bryant HE (2020) Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy. Front Mol Biosci 7:191. https:\/\/doi.org\/10.3389\/fmolb.2020.00191","journal-title":"Front Mol Biosci"},{"key":"12223_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.dnarep.2016.05.003","volume":"44","author":"RD Wood","year":"2016","unstructured":"Wood RD, Doubli\u00e9 S (2016) DNA polymerase \u03b8 (POLQ), double-strand break repair, and cancer. DNA Repair (Amst) 44:22\u201332. https:\/\/doi.org\/10.1016\/j.dnarep.2016.05.003","journal-title":"DNA Repair (Amst)"},{"issue":"3","key":"12223_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nsmb.2501","volume":"20","author":"M Berti","year":"2013","unstructured":"Berti M, Ray Chaudhuri A, Thangavel S, Gomathinayagam S, Kenig S, Vujanovic M et al (2013) Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat Struct Mol Biol 20(3):347\u2013354. https:\/\/doi.org\/10.1038\/nsmb.2501","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"12223_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0921-8777(00)00016-1","volume":"460","author":"S Shall","year":"2000","unstructured":"Shall S, de Murcia G (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460(1):1\u201315. https:\/\/doi.org\/10.1016\/s0921-8777(00)00016-1","journal-title":"Mutat Res"},{"issue":"1","key":"12223_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/s41467-020-15429-z","volume":"11","author":"H Zuo","year":"2020","unstructured":"Zuo H, Yang D, Yang Q, Tang H, Fu Y-X, Wan Y (2020) Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat Commun 11(1):1578. https:\/\/doi.org\/10.1038\/s41467-020-15429-z","journal-title":"Nat Commun"},{"issue":"2","key":"12223_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-014-3230-1","volume":"149","author":"AR Green","year":"2015","unstructured":"Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD et al (2015) Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat 149(2):353\u2013362. https:\/\/doi.org\/10.1007\/s10549-014-3230-1","journal-title":"Breast Cancer Res Treat"},{"key":"12223_CR26","doi-asserted-by":"publisher","unstructured":"Sklias T, Vardas V, Pantazaka E, Christopoulou A, Georgoulias V, Kotsakis A et al (2022) PARP-1 expression and brca1 mutations in breast cancer patients\u2019 CTCs. Cancers [Internet] 14(7). https:\/\/doi.org\/10.3390\/cancers14071731","DOI":"10.3390\/cancers14071731"},{"issue":"6","key":"12223_CR27","first-page":"7059","volume":"8","author":"L Zhai","year":"2015","unstructured":"Zhai L, Li S, Li H, Zheng Y, Lang R, Fan Y et al (2015) Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3\u2019 untranslated region and their association with PARP1 expression in breast cancer patients. Int J Clin Exp Pathol 8(6):7059\u20137071","journal-title":"Int J Clin Exp Pathol"},{"issue":"65","key":"12223_CR28","doi-asserted-by":"publisher","first-page":"108712","DOI":"10.18632\/oncotarget.21561","volume":"8","author":"L Deng","year":"2017","unstructured":"Deng L, Lei Q, Wang Y, Wang Z, Xie G, Zhong X et al (2017) Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis. Oncotarget 8(65):108712\u2013108725. https:\/\/doi.org\/10.18632\/oncotarget.21561","journal-title":"Oncotarget"},{"issue":"3","key":"12223_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-015-3359-6","volume":"150","author":"J Stanley","year":"2015","unstructured":"Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A et al (2015) PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Res Treat 150(3):569\u2013579. https:\/\/doi.org\/10.1007\/s10549-015-3359-6","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"12223_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1158\/1541-7786.MCR-16-0287-T","volume":"15","author":"ME Wielgos","year":"2017","unstructured":"Wielgos ME, Rajbhandari R, Cooper TS, Wei S, Nozell S, Yang ES (2017) Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors. Mol Cancer Res 15(3):340\u2013347. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0287-T","journal-title":"Mol Cancer Res"},{"issue":"5","key":"12223_CR31","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/annonc\/mdr361","volume":"23","author":"F Rojo","year":"2012","unstructured":"Rojo F, Garc\u00eda-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S et al (2012) Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 23(5):1156\u20131164. https:\/\/doi.org\/10.1093\/annonc\/mdr361","journal-title":"Ann Oncol"},{"issue":"10","key":"12223_CR32","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1541-7786.MCR-21-0103","volume":"19","author":"SS Gadad","year":"2021","unstructured":"Gadad SS, Camacho CV, Malladi V, Hutti CR, Nagari A, Kraus WL (2021) PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor \u03b1\u2013Positive Breast Cancer Cells. Mol Cancer Res 19(10):1688\u20131698. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0103","journal-title":"Mol Cancer Res"},{"issue":"8","key":"12223_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/bjc.2011.382","volume":"105","author":"M Javle","year":"2011","unstructured":"Javle M, Curtin NJ (2011) The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105(8):1114\u20131122. https:\/\/doi.org\/10.1038\/bjc.2011.382","journal-title":"Br J Cancer"},{"key":"12223_CR34","doi-asserted-by":"publisher","unstructured":"Li X, Zou L, BRCAness (2024) DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality. J Clin Invest 134(14). https:\/\/doi.org\/10.1172\/jci181062","DOI":"10.1172\/jci181062"},{"issue":"1","key":"12223_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41523-022-00411-3","volume":"8","author":"N Tung","year":"2022","unstructured":"Tung N, Garber JE (2022) PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer 8(1):47. https:\/\/doi.org\/10.1038\/s41523-022-00411-3","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"12223_CR36","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/stem.2116","volume":"33","author":"B-H Jiang","year":"2015","unstructured":"Jiang B-H, Chen W-Y, Li H-Y, Chien Y, Chang W-C, Hsieh P-C et al (2015) CHD1L Regulated PARP1-Driven Pluripotency and Chromatin Remodeling During the Early-Stage Cell Reprogramming. Stem Cells 33(10):2961\u20132972. https:\/\/doi.org\/10.1002\/stem.2116","journal-title":"Stem Cells"},{"issue":"1","key":"12223_CR37","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1038\/s41598-023-49156-4","volume":"14","author":"K Pan","year":"2024","unstructured":"Pan K, Li X, He J, Lei Y, Yang Y, Jiang D et al (2024) Value of the NF-\u03baB signalling pathway and the DNA repair gene PARP1 in predicting distant metastasis after breast cancer surgery. Sci Rep 14(1):4402. https:\/\/doi.org\/10.1038\/s41598-023-49156-4","journal-title":"Sci Rep"},{"key":"12223_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0118715206381898250428064533","volume":"25","author":"T Hongjun","year":"2025","unstructured":"Hongjun T, Jingsheng C, Kangwei J, Jiangtao H, Fangming T, Dongbing L et al (2025) Unraveling the Resistance: Challenges and Advances in PARP Inhibitor Therapy for BRCA1\/2 Breast Cancer. Anti-cancer Agents Med Chem 25:1\u201310. https:\/\/doi.org\/10.2174\/0118715206381898250428064533","journal-title":"Anti-cancer Agents Med Chem"},{"issue":"6","key":"12223_CR39","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","volume":"33","author":"E Gogola","year":"2018","unstructured":"Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R et al (2018) Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell 33(6):1078\u201393e12. https:\/\/doi.org\/10.1016\/j.ccell.2018.05.008","journal-title":"Cancer Cell"},{"issue":"5","key":"12223_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F et al (2024) PARP Inhibitors for Breast Cancer Treatment: A Review. JAMA Oncol 10(5):658\u2013670. https:\/\/doi.org\/10.1001\/jamaoncol.2023.7322","journal-title":"JAMA Oncol"},{"issue":"1","key":"12223_CR41","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.1038\/s41598-020-64473-8","volume":"10","author":"Y Liao","year":"2020","unstructured":"Liao Y, Liao Y, Li J, Xiong J, Fan Y (2020) Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline\/taxane based adjuvant chemotherapy. Sci Rep 10(1):7349. https:\/\/doi.org\/10.1038\/s41598-020-64473-8","journal-title":"Sci Rep"},{"issue":"2","key":"12223_CR42","doi-asserted-by":"publisher","first-page":"e0172413","DOI":"10.1371\/journal.pone.0172413","volume":"12","author":"W Qiao","year":"2017","unstructured":"Qiao W, Pan L, Kou C, Li K, Yang M (2017) Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis. PLoS ONE 12(2):e0172413. https:\/\/doi.org\/10.1371\/journal.pone.0172413","journal-title":"PLoS ONE"},{"issue":"3","key":"12223_CR43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/2159-8290.CD-NB2018-008","volume":"8","author":"PARP First","year":"2018","unstructured":"First PARP, Inhibitor Ok\u2019d for Breast Cancer (2018) Cancer Discov 8(3):256\u2013257. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2018-008","journal-title":"Cancer Discov"},{"issue":"2Supplement","key":"12223_CR44","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/0008-5472.SABCS-1038","volume":"69","author":"RS Finn","year":"2009","unstructured":"Finn RS, Lau A, Kalous O, Conklin D, Dering J, Knights C et al (2009) Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents. Cancer Res 69(2Supplement):1038. https:\/\/doi.org\/10.1158\/0008-5472.SABCS-1038","journal-title":"Cancer Res"},{"issue":"34","key":"12223_CR45","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1200\/JCO.2011.38.1988","volume":"29","author":"L Ozreti\u0107","year":"2011","unstructured":"Ozreti\u0107 L, Rhiem K, Huss S, Wappenschmidt B, Markiefka B, Sinn P et al (2011) High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive for BRCA1- and BRCA2-Deficient Breast Cancer. J Clin Oncol 29(34):4586\u20134588. https:\/\/doi.org\/10.1200\/JCO.2011.38.1988","journal-title":"J Clin Oncol"},{"issue":"8","key":"12223_CR46","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/pai.0000000000000124","volume":"23","author":"HA Aiad","year":"2015","unstructured":"Aiad HA, Kandil MA, El-Tahmody MA, Abulkheir IL, Abulkasem FM, Elmansori AA et al (2015) The prognostic and predictive significance of PARP-1 in locally advanced breast cancer of Egyptian patients receiving neoadjuvant chemotherapy. Appl Immunohistochem Mol Morphol 23(8):571\u2013579. https:\/\/doi.org\/10.1097\/pai.0000000000000124","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"12223_CR47","doi-asserted-by":"publisher","first-page":"1198948","DOI":"10.3389\/fphar.2023.1198948","volume":"14","author":"WH Li","year":"2023","unstructured":"Li WH, Wang F, Song GY, Yu QH, Du RP, Xu P (2023) PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities. Front Pharmacol 14:1198948. https:\/\/doi.org\/10.3389\/fphar.2023.1198948","journal-title":"Front Pharmacol"},{"issue":"5","key":"12223_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1101\/gad.183509.111","volume":"26","author":"X Luo","year":"2012","unstructured":"Luo X, Kraus WL (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26(5):417\u2013432. https:\/\/doi.org\/10.1101\/gad.183509.111","journal-title":"Genes Dev"},{"issue":"1","key":"12223_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/09674845.2013.11669927","volume":"70","author":"MR Salehan","year":"2013","unstructured":"Salehan MR, Morse HR (2013) DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 70(1):31\u201340. https:\/\/doi.org\/10.1080\/09674845.2013.11669927","journal-title":"Br J Biomed Sci"},{"issue":"8","key":"12223_CR50","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1111\/j.1742-4658.2005.04628.x","volume":"272","author":"JL Parsons","year":"2005","unstructured":"Parsons JL, Dianova II, Allinson SL, Dianov GL (2005) Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts. FEBS J 272(8):2012\u20132021. https:\/\/doi.org\/10.1111\/j.1742-4658.2005.04628.x","journal-title":"FEBS J"},{"issue":"5","key":"12223_CR51","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/1535-7163.Mct-14-0810","volume":"14","author":"O Erice","year":"2015","unstructured":"Erice O, Smith MP, White R, Goicoechea I, Barriuso J, Jones C et al (2015) MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Mol Cancer Ther 14(5):1236\u20131246. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-0810","journal-title":"Mol Cancer Ther"},{"key":"12223_CR52","doi-asserted-by":"publisher","unstructured":"Pulliam N, Tang J, Wang W, Fang F, Sood R, O\u2019Hagan HM et al (2019) Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells. Cancers (Basel) 11(1). https:\/\/doi.org\/10.3390\/cancers11010043","DOI":"10.3390\/cancers11010043"},{"issue":"4","key":"12223_CR53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.37349\/etat.2021.00052","volume":"2","author":"KA Altwegg","year":"2021","unstructured":"Altwegg KA, Vadlamudi RK (2021) Role of estrogen receptor coregulators in endocrine resistant breast cancer. Explor Target Antitumor Ther 2(4):385\u2013400. https:\/\/doi.org\/10.37349\/etat.2021.00052","journal-title":"Explor Target Antitumor Ther"},{"issue":"1","key":"12223_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-019-05286-w","volume":"177","author":"A Prawira","year":"2019","unstructured":"Prawira A, Munusamy P, Yuan J, Chan CHT, Koh GL, Shuen TWH et al (2019) Assessment of PARP4 as a candidate breast cancer susceptibility gene. Breast Cancer Res Treat 177(1):145\u2013153. https:\/\/doi.org\/10.1007\/s10549-019-05286-w","journal-title":"Breast Cancer Res Treat"},{"key":"12223_CR55","doi-asserted-by":"publisher","unstructured":"Piombino C, Cortesi L (2022) Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors. Cancers [Internet]. 14(11):2804. https:\/\/doi.org\/10.3390\/cancers14112804","DOI":"10.3390\/cancers14112804"},{"issue":"6","key":"12223_CR56","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jmcb\/mjab018","volume":"13","author":"L Duan","year":"2021","unstructured":"Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CG (2021) Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol 13(6):433\u2013444. https:\/\/doi.org\/10.1093\/jmcb\/mjab018","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"12223_CR57","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/med.22069","volume":"45","author":"Y-R Bai","year":"2025","unstructured":"Bai Y-R, Yang W-G, Jia R, Sun J-S, Shen D-D, Liu H-M et al (2025) The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Med Res Rev 45(1):214\u2013273. https:\/\/doi.org\/10.1002\/med.22069","journal-title":"Med Res Rev"},{"issue":"23","key":"12223_CR58","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1158\/1078-0432.CCR-16-0247","volume":"22","author":"EH Stover","year":"2016","unstructured":"Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM (2016) Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res 22(23):5651\u20135660. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0247","journal-title":"Clin Cancer Res"},{"issue":"16","key":"12223_CR59","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.18632\/oncotarget.1955","volume":"5","author":"K Feldinger","year":"2014","unstructured":"Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 2014 Aug 30;5(16):6633-46. PMID: 24952873; PMCID: PMC4196152. https:\/\/doi.org\/10.18632\/oncotarget.1955","journal-title":"Oncotarget"},{"key":"12223_CR60","doi-asserted-by":"crossref","unstructured":"Nakagawa Y, Sedukhina AS, Okamoto N, Nagasawa S, Suzuki N, Ohta T et al (2015) NF-kB signaling mediates acquired resistance after PARP inhibition. Oncotarget; Vol 6, No 6","DOI":"10.18632\/oncotarget.2868"},{"issue":"288","key":"12223_CR61","doi-asserted-by":"publisher","first-page":"pe27","DOI":"10.1126\/stke.2882005pe27","volume":"2005","author":"DK Biswas","year":"2005","unstructured":"Biswas DK, Singh S, Shi Q, Pardee AB, Iglehart JD (2005) Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE 2005(288):pe27. https:\/\/doi.org\/10.1126\/stke.2882005pe27","journal-title":"Sci STKE"},{"key":"12223_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jare.2023.02.015","volume":"55","author":"A Mazurakova","year":"2024","unstructured":"Mazurakova A, Koklesova L, Csizm\u00e1r SH, Samec M, Brockmueller A, \u0160udomov\u00e1 M et al (2024) Significance of flavonoids targeting PI3K\/Akt\/HIF-1\u03b1 signaling pathway in therapy-resistant cancer cells - A potential contribution to the predictive, preventive, and personalized medicine. J Adv Res 55:103\u2013118. https:\/\/doi.org\/10.1016\/j.jare.2023.02.015","journal-title":"J Adv Res"},{"issue":"23","key":"12223_CR63","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1158\/0008-5472.CAN-23-0485","volume":"83","author":"LP Ferretti","year":"2023","unstructured":"Ferretti LP, B\u00f6hi F, Leslie Pedrioli DM, Cheng PF, Ferrari E, Baumgaertner P et al (2023) Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma. Cancer Res 83(23):3974\u20133988. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0485","journal-title":"Cancer Res"},{"issue":"24","key":"12223_CR64","doi-asserted-by":"publisher","first-page":"11157","DOI":"10.1111\/jcmm.17037","volume":"25","author":"S Zhou","year":"2021","unstructured":"Zhou S, Dai Z, Wang L, Gao X, Yang L, Wang Z et al (2021) MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM\/ATR and PI3K\/AKT pathways. J Cell Mol Med 25(24):11157\u201311169. https:\/\/doi.org\/10.1111\/jcmm.17037","journal-title":"J Cell Mol Med"},{"issue":"1","key":"12223_CR65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1593\/neo.131694","volume":"16","author":"P De","year":"2014","unstructured":"De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N (2014) Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of parp inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia 16(1):43\u2013W19. https:\/\/doi.org\/10.1593\/neo.131694","journal-title":"Neoplasia"},{"issue":"8","key":"12223_CR66","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1158\/1078-0432.CCR-14-2616","volume":"21","author":"AJ Lombardi","year":"2015","unstructured":"Lombardi AJ, Hoskins EE, Foglesong GD, Wikenheiser-Brokamp KA, Wiesm\u00fcller L, Hanenberg H et al (2015) Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in fanconi anemia head and neck cancers. Clin Cancer Res 21(8):1962\u20131972. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2616","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"12223_CR67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","volume":"51","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Arisa O, Peer CJ, Fojo A, Figg WD (2024) PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin Oncol 51(1\u20132):19\u201324. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.09.005","journal-title":"Semin Oncol"},{"issue":"8","key":"12223_CR68","first-page":"487","volume":"23","author":"M Boulos","year":"2022","unstructured":"Boulos M, Moujaes E, Nsouli G, Tfayli A, Kourie HR (2022) Talazoparib in BRCA-mutated advanced breast cancer. is earlier better? Pharmacogenomics 23(8):487\u2013492","journal-title":"Is Earlier Better? Pharmacogenomics"},{"issue":"25","key":"12223_CR69","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"AN Tutt","year":"2021","unstructured":"Tutt AN, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"1","key":"12223_CR70","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/gco.0000000000000600","volume":"32","author":"K Kubalanza","year":"2020","unstructured":"Kubalanza K, Konecny GE (2020) Mechanisms of PARP inhibitor resistance in ovarian cancer. Curr Opin Obstet Gynecol 32(1):36\u201341. https:\/\/doi.org\/10.1097\/gco.0000000000000600","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"4","key":"12223_CR71","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.7150\/jca.65650","volume":"13","author":"H Zong","year":"2022","unstructured":"Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J et al (2022) Comprehensive analysis of somatic reversion mutations in homologous recombination repair (HRR) Genes in a large cohort of chinese pan-cancer patients. J Cancer 13(4):1119\u20131129. https:\/\/doi.org\/10.7150\/jca.65650","journal-title":"J Cancer"},{"issue":"1","key":"12223_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molcel.2019.09.024","volume":"77","author":"E Callen","year":"2020","unstructured":"Callen E, Zong D, Wu W, Wong N, Stanlie A, Ishikawa M et al (2020) 53BP1 enforces distinct pre- and post-resection blocks on homologous recombination. Mol Cell 77(1):26\u201338e7. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.024","journal-title":"Mol Cell"},{"issue":"6","key":"12223_CR73","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nsmb.1831","volume":"17","author":"P Bouwman","year":"2010","unstructured":"Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H et al (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17(6):688\u2013695. https:\/\/doi.org\/10.1038\/nsmb.1831","journal-title":"Nat Struct Mol Biol"},{"issue":"13","key":"12223_CR74","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1016\/j.celrep.2018.08.086","volume":"24","author":"J Nacson","year":"2018","unstructured":"Nacson J, Krais JJ, Bernhardy AJ, Clausen E, Feng W, Wang Y et al (2018) BRCA1 mutation-specific responses to 53bp1 loss-induced homologous recombination and parp inhibitor resistance. Cell Rep 24(13):3513\u201327e7. https:\/\/doi.org\/10.1016\/j.celrep.2018.08.086","journal-title":"Cell Rep"},{"issue":"1","key":"12223_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.Cd-12-0049","volume":"3","author":"JE Jaspers","year":"2013","unstructured":"Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA et al (2013) Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3(1):68\u201381. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0049","journal-title":"Cancer Discov"},{"issue":"7716","key":"12223_CR76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-018-0324-7","volume":"560","author":"Z Mirman","year":"2018","unstructured":"Mirman Z, Lottersberger F, Takai H, Kibe T, Gong Y, Takai K et al (2018) 53BP1\u2013RIF1\u2013shieldin counteracts DSB resection through CST- and Pol\u03b1-dependent fill-in. Nature 560(7716):112\u2013116. https:\/\/doi.org\/10.1038\/s41586-018-0324-7","journal-title":"Nature"},{"issue":"11","key":"12223_CR77","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1021\/acs.molpharmaceut.8b00742","volume":"15","author":"MC de Gooijer","year":"2018","unstructured":"de Gooijer MC, Buil LCM, \u00c7itirikkaya CH, Hermans J, Beijnen JH, van Tellingen O (2018) ABCB1 attenuates the brain penetration of the PARP inhibitor AZD2461. Mol Pharm 15(11):5236\u20135243. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00742","journal-title":"Mol Pharm"},{"issue":"1","key":"12223_CR78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11095-014-1442-z","volume":"32","author":"S Durmus","year":"2015","unstructured":"Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH (2015) Breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res 32(1):37\u201346. https:\/\/doi.org\/10.1007\/s11095-014-1442-z","journal-title":"Pharm Res"},{"issue":"27","key":"12223_CR79","doi-asserted-by":"publisher","first-page":"8409","DOI":"10.1073\/pnas.1500223112","volume":"112","author":"L Henneman","year":"2015","unstructured":"Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP et al (2015) Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc Natl Acad Sci 112(27):8409\u20138414. https:\/\/doi.org\/10.1073\/pnas.1500223112","journal-title":"Proc Natl Acad Sci"},{"issue":"20","key":"12223_CR80","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1158\/0008-5472.Can-15-3240","volume":"76","author":"OC Oplustil","year":"2016","unstructured":"Oplustil OC, Rulten L, Cranston SL, Odedra AN, Brown R, Jaspers H (2016) The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer Res 76(20):6084\u20136094. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-3240","journal-title":"Cancer Res"},{"key":"12223_CR81","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/ott.S457749","volume":"17","author":"OR Ajuwon","year":"2024","unstructured":"Ajuwon OR, Nsole-Biteghe FA, Ndong JD, Davids LM, Ajiboye BO, Brai B et al (2024) Nrf2-mediated antioxidant response and drug efflux transporters upregulation as possible mechanisms of resistance in photodynamic therapy of cancers. Onco Targets Ther 17:605\u2013627. https:\/\/doi.org\/10.2147\/ott.S457749","journal-title":"Onco Targets Ther"},{"key":"12223_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","volume":"71","author":"B Haynes","year":"2018","unstructured":"Haynes B, Murai J, Lee JM (2018) Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev 71:1\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2018.09.003","journal-title":"Cancer Treat Rev"},{"key":"12223_CR83","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fpls.2020.00262","volume":"11","author":"A Hugues","year":"2020","unstructured":"Hugues A, Jacobs CS, Roudier F. Mitotic Inheritance of PRC2-Mediated Silencing: Mechanistic Insights and Developmental Perspectives. Front Plant Sci. 2020 Mar 9;11:262. PMID: 32211012; PMCID: PMC7075419. https:\/\/doi.org\/10.3389\/fpls.2020.00262","journal-title":"Front Plant Sci"},{"issue":"1","key":"12223_CR84","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41467-017-01180-5","volume":"8","author":"D Lema\u00e7on","year":"2017","unstructured":"Lema\u00e7on D, Jackson J, Quinet A, Brickner JR, Li S, Yazinski S et al (2017) MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells. Nat Commun 8(1):860. https:\/\/doi.org\/10.1038\/s41467-017-01180-5","journal-title":"Nat Commun"},{"issue":"7","key":"12223_CR85","doi-asserted-by":"publisher","first-page":"e49367","DOI":"10.15252\/embr.201949367","volume":"21","author":"B Pardo","year":"2020","unstructured":"Pardo B, Moriel-Carretero M, Vicat T, Aguilera A, Pasero P (2020) Homologous recombination and Mus81 promote replication completion in response to replication fork blockage. EMBO Rep 21(7):e49367. https:\/\/doi.org\/10.15252\/embr.201949367","journal-title":"EMBO Rep"},{"issue":"13","key":"12223_CR86","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.1093\/nar\/gkad470","volume":"51","author":"F Blandino","year":"2023","unstructured":"Blandino F, Malacaria E, Figlioli C, Noto A, Pugliese Giusj M, Franchitto A et al (2023) Phosphorylation status of MUS81 is a modifier of Olaparib sensitivity in BRCA2-deficient cells. Nucleic Acids Res 51(13):6723\u20136737. https:\/\/doi.org\/10.1093\/nar\/gkad470","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"12223_CR87","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1038\/s41467-024-50158-7","volume":"15","author":"U Vekariya","year":"2024","unstructured":"Vekariya U, Minakhin L, Chandramouly G, Tyagi M, Kent T, Sullivan-Reed K et al (2024) PARG is essential for Pol\u03b8-mediated DNA end-joining by removing repressive poly-ADP-ribose marks. Nat Commun 15(1):5822. https:\/\/doi.org\/10.1038\/s41467-024-50158-7","journal-title":"Nat Commun"},{"issue":"1","key":"12223_CR88","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1038\/s41467-019-13508-4","volume":"10","author":"JH Houl","year":"2019","unstructured":"Houl JH, Ye Z, Brosey CA, Balapiti-Modarage LPF, Namjoshi S, Bacolla A et al (2019) Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nat Commun 10(1):5654. https:\/\/doi.org\/10.1038\/s41467-019-13508-4","journal-title":"Nat Commun"},{"issue":"1","key":"12223_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-022-06780-4","volume":"197","author":"T Gupta","year":"2023","unstructured":"Gupta T, Vinayak S, Telli M (2023) Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat 197(1):51\u201356. https:\/\/doi.org\/10.1007\/s10549-022-06780-4","journal-title":"Breast Cancer Res Treat"},{"key":"12223_CR90","doi-asserted-by":"publisher","first-page":"117955492199628","DOI":"10.1177\/1179554921996288","volume":"15","author":"Z Wu","year":"2021","unstructured":"Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z et al (2021) The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights: Oncol 15:1179554921996288. https:\/\/doi.org\/10.1177\/1179554921996288","journal-title":"Clin Med Insights: Oncol"},{"issue":"6","key":"12223_CR91","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/CCO.0000000000000680","volume":"32","author":"A Goncalves","year":"2020","unstructured":"Goncalves A, Mezni E, Bertucci F (2020) Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. Curr Opin Oncol 32(6):585\u2013593. https:\/\/doi.org\/10.1097\/CCO.0000000000000680","journal-title":"Curr Opin Oncol"},{"key":"12223_CR92","doi-asserted-by":"publisher","unstructured":"Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV et al (2022) PARP inhibitors resistance: mechanisms and perspectives. Cancers (Basel) 14(6). https:\/\/doi.org\/10.3390\/cancers14061420","DOI":"10.3390\/cancers14061420"},{"issue":"8","key":"12223_CR93","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/0008-5472.Can-09-3422","volume":"70","author":"SC Shuck","year":"2010","unstructured":"Shuck SC, Turchi JJ (2010) Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function. Cancer Res 70(8):3189\u20133198. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3422","journal-title":"Cancer Res"},{"issue":"6","key":"12223_CR94","doi-asserted-by":"publisher","first-page":"1805256","DOI":"10.1080\/23723556.2020.1805256","volume":"7","author":"J Xuan","year":"2020","unstructured":"Xuan J, Pearson RB, Sanij E (2020) CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer. Mol Cell Oncol 7(6):1805256. https:\/\/doi.org\/10.1080\/23723556.2020.1805256","journal-title":"Mol Cell Oncol"},{"issue":"7","key":"12223_CR95","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng C-X (2022) Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci 18(7):3019\u20133033. https:\/\/doi.org\/10.7150\/ijbs.72534","journal-title":"Int J Biol Sci"},{"key":"12223_CR96","doi-asserted-by":"publisher","unstructured":"Ghonim MA, Ibba SV, Tarhuni AF, Errami Y, Luu HH, Dean MJ et al (2021) Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J Immunother Cancer 9(1). https:\/\/doi.org\/10.1136\/jitc-2020-001643","DOI":"10.1136\/jitc-2020-001643"},{"key":"12223_CR97","doi-asserted-by":"publisher","unstructured":"Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E et al (2021) Cell-autonomous inflammation of <\u2009em>BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance\u2009<\u2009em>via STING. Cell Rep 36(3). https:\/\/doi.org\/10.1016\/j.celrep.2021.109412","DOI":"10.1016\/j.celrep.2021.109412"},{"key":"12223_CR98","doi-asserted-by":"publisher","unstructured":"Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z et al (2023) STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. J Immunother Cancer 11(1). https:\/\/doi.org\/10.1136\/jitc-2022-005627","DOI":"10.1136\/jitc-2022-005627"},{"issue":"9","key":"12223_CR99","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.3390\/cancers15092662","volume":"15","author":"T Inoue","year":"2023","unstructured":"Inoue T, Sekito S, Kageyama T, Sugino Y, Sasaki T (2023) Roles of the PARP inhibitor in BRCA1 and BRCA2 pathogenic mutated metastatic prostate cancer: direct functions and modification of the tumor microenvironment. Cancers [Internet] 15(9):2662. https:\/\/doi.org\/10.3390\/cancers15092662","journal-title":"Cancers [Internet]"},{"issue":"3","key":"12223_CR100","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/path.6043","volume":"259","author":"M Fern\u00e1ndez-Cort\u00e9s","year":"2023","unstructured":"Fern\u00e1ndez-Cort\u00e9s M, Delgado-Bellido D, Berm\u00fadez-Jim\u00e9nez E, Paramio JM, O\u2019Valle F, Vinckier S et al (2023) PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry. J Pathol 259(3):318\u2013330. https:\/\/doi.org\/10.1002\/path.6043","journal-title":"J Pathol"},{"key":"12223_CR101","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fphar.2012.00202","volume":"3","author":"A Lovato","year":"2012","unstructured":"Lovato A, Panasci L, Witcher M. Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors? Front Pharmacol. 2012 Dec 27;3:202. PMID: 23293602; PMCID: PMC3530734. https:\/\/doi.org\/10.3389\/fphar.2012.00202","journal-title":"Front Pharmacol"},{"issue":"10","key":"12223_CR102","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.trecan.2021.05.004","volume":"7","author":"MM Pham","year":"2021","unstructured":"Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA (2021) Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer 7(10):958\u2013970. https:\/\/doi.org\/10.1016\/j.trecan.2021.05.004","journal-title":"Trends Cancer"},{"issue":"18","key":"12223_CR103","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/0008-5472.Can-21-0774","volume":"81","author":"K Nesic","year":"2021","unstructured":"Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY et al (2021) Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. Cancer Res 81(18):4709\u20134722. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-0774","journal-title":"Cancer Res"},{"issue":"1","key":"12223_CR104","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho G-Y, Harrell MI et al (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9(1):3970. https:\/\/doi.org\/10.1038\/s41467-018-05564-z","journal-title":"Nat Commun"},{"issue":"24","key":"12223_CR105","doi-asserted-by":"publisher","first-page":"16464","DOI":"10.1021\/acs.jmedchem.3c00865","volume":"66","author":"F Liu","year":"2023","unstructured":"Liu F, Chen J, Li X, Liu R, Zhang Y, Gao C et al (2023) Advances in development of selective antitumor inhibitors that target PARP-1. J Med Chem 66(24):16464\u201316483. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00865","journal-title":"J Med Chem"},{"issue":"2","key":"12223_CR106","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/bcp.15015","volume":"88","author":"D Sandhu","year":"2022","unstructured":"Sandhu D, Antolin AA, Cox AR, Jones AM (2022) Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale. Br J Clin Pharmacol 88(2):742\u2013752. https:\/\/doi.org\/10.1111\/bcp.15015","journal-title":"Br J Clin Pharmacol"},{"key":"12223_CR107","doi-asserted-by":"publisher","unstructured":"Martorana F, Da Silva LA, Sessa C, Colombo I (2022) Everything Comes with a price: the toxicity profile of dna-damage response targeting agents. Cancers (Basel) 14(4). https:\/\/doi.org\/10.3390\/cancers14040953","DOI":"10.3390\/cancers14040953"},{"issue":"22","key":"12223_CR108","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1158\/1078-0432.Ccr-19-1089","volume":"25","author":"A Thomas","year":"2019","unstructured":"Thomas A, Pommier Y (2019) Targeting topoisomerase I in the era of precision medicine. Clin Cancer Res 25(22):6581\u20136589. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1089","journal-title":"Clin Cancer Res"},{"issue":"4","key":"12223_CR109","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/10781552221073990","volume":"28","author":"RR George","year":"2022","unstructured":"George RR, Thomas R, Davice A, Mathew MS (2022) Veliparib for the treatment of solid malignancies. J Oncol Pharm Pract 28(4):924\u2013934","journal-title":"J Oncol Pharm Pract"},{"key":"12223_CR110","unstructured":"Niraparib (2006) Drugs and Lactation Database (LactMed\u00ae). Bethesda (MD). National Institute of Child Health and Human Development"},{"issue":"2","key":"12223_CR111","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/onco.13585","volume":"26","author":"MS Anscher","year":"2021","unstructured":"Anscher MS, Chang E, Gao X, Gong Y, Weinstock C, Bloomquist E et al (2021) FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castrate-resistant prostate cancer. Oncologist 26(2):139\u2013146. https:\/\/doi.org\/10.1002\/onco.13585","journal-title":"Oncologist"},{"issue":"6","key":"12223_CR112","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1358\/dot.2022.58.6.3389001","volume":"58","author":"A Skrzypczyk-Ostaszewicz","year":"2022","unstructured":"Skrzypczyk-Ostaszewicz A (2022) Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer. Drugs Today (Barc) 58(6):299\u2013309. https:\/\/doi.org\/10.1358\/dot.2022.58.6.3389001","journal-title":"Drugs Today (Barc)"},{"issue":"10","key":"12223_CR113","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A, Fuzuloparib (2021) First approval drugs 81(10):1221\u20131226. https:\/\/doi.org\/10.1007\/s40265-021-01541-x","journal-title":"First Approval Drugs"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12223-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:50:17Z","timestamp":1783014617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12223-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12223"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12223-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"1075"}}